BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst Pharmaceuticals (Nasdaq: BCRX) announced the granting of stock options and restricted stock units (RSUs) to 10 newly-hired employees as employment inducements. The compensation committee approved options to purchase 36,700 shares and RSUs covering 89,750 shares of common stock.
The options were granted with an exercise price of $7.95 per share, matching BioCryst's closing price on August 1, 2025. Both options and RSUs will vest over four equal annual installments, starting one year from the grant date, with options having a 10-year term. These grants were made under BioCryst's Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
BioCryst Pharmaceuticals (Nasdaq: BCRX) ha annunciato la concessione di opzioni su azioni e unit脿 azionarie vincolate (RSU) a 10 nuovi dipendenti come incentivo all'assunzione. Il comitato per la remunerazione ha approvato opzioni per l'acquisto di 36.700 azioni e RSU per un totale di 89.750 azioni ordinarie.
Le opzioni sono state concesse con un prezzo di esercizio di 7,95 $ per azione, corrispondente al prezzo di chiusura di BioCryst del 1掳 agosto 2025. Sia le opzioni sia le RSU matureranno in quattro rate annuali uguali, a partire da un anno dalla data di concessione, con un termine di 10 anni per le opzioni. Questi incentivi sono stati concessi nell'ambito del Piano di Incentivi Azionari di BioCryst, in conformit脿 con la Regola di quotazione Nasdaq 5635(c)(4).
BioCryst Pharmaceuticals (Nasdaq: BCRX) anunci贸 la concesi贸n de opciones sobre acciones y unidades restringidas de acciones (RSU) a 10 empleados reci茅n contratados como incentivos laborales. El comit茅 de compensaci贸n aprob贸 opciones para comprar 36,700 acciones y RSUs que cubren 89,750 acciones comunes.
Las opciones se otorgaron con un precio de ejercicio de $7.95 por acci贸n, igualando el precio de cierre de BioCryst el 1 de agosto de 2025. Tanto las opciones como las RSUs se consolidar谩n en cuatro cuotas anuales iguales, comenzando un a帽o despu茅s de la fecha de concesi贸n, con un plazo de 10 a帽os para las opciones. Estas concesiones se realizaron bajo el Plan de Incentivos de Capital por Inducci贸n de BioCryst, conforme a la Regla de Cotizaci贸n Nasdaq 5635(c)(4).
BioCryst Pharmaceuticals (雮橃姢雼�: BCRX)電� 鞁犼窚 毂勳毄 歆侅洂 10氇呾棎瓴� 瓿犾毄 鞙犾澑毂呾溂搿� 欤检嫕 毵れ垬靹犿儩甓岅臣 鞝滍暅 欤检嫕 雼渼(RSU)毳� 攵�鞐枅雼り碃 氚滍憸頄堨姷雼堧嫟. 氤挫儊鞙勳洂須岆姅 36,700欤�鞚� 欤检嫕 毵れ垬靹犿儩甓岅臣 89,750欤�鞚� 氤错喌欤� RSU毳� 鞀轨澑頄堨姷雼堧嫟.
毵れ垬靹犿儩甓� 頄夓偓臧�瓴╈潃 2025雲� 8鞗� 1鞚� BioCryst鞚� 膦呹皜鞚� 欤茧嫻 7.95雼煬搿� 攵�鞐悩鞐堨姷雼堧嫟. 毵れ垬靹犿儩甓岅臣 RSU電� 氇憪 攵�鞐澕搿滊秬韯� 1雲� 頉勲秬韯� 鞁滌瀾頃橃棳 4雲勱皠 毵る厔 霃欖澕頃� 牍勳湪搿� 甓岆Μ臧� 旆摑霅橂┌, 毵れ垬靹犿儩甓岇潣 鞙犿毃旮瓣皠鞚� 10雲勳瀰雼堧嫟. 鞚� 攵�鞐姅 雮橃姢雼� 靸侅灔 攴滌箼 5635(c)(4)鞐� 霐半澕 BioCryst鞚� 鞙犾澑 欤检嫕 鞚胳劶韹半笇 瓿勴殟鞐� 霐半澕 鞚措（鞏挫鞀惦媹雼�.
BioCryst Pharmaceuticals (Nasdaq : BCRX) a annonc茅 l鈥檃ttribution d鈥檕ptions d鈥檃chat d鈥檃ctions et d鈥檜nit茅s d鈥檃ctions restreintes (RSU) 脿 10 nouveaux employ茅s en guise d鈥檌ncitations 脿 l鈥檈mbauche. Le comit茅 de r茅mun茅ration a approuv茅 des options d鈥檃chat de 36 700 actions et des RSU couvrant 89 750 actions ordinaires.
Les options ont 茅t茅 accord茅es 脿 un prix d鈥檈xercice de 7,95 $ par action, correspondant au cours de cl么ture de BioCryst au 1er ao没t 2025. Les options comme les RSU seront acquises par tranches 茅gales sur quatre ans, 脿 partir d鈥檜n an apr猫s la date d鈥檃ttribution, les options ayant une dur茅e de 10 ans. Ces attributions ont 茅t茅 effectu茅es dans le cadre du Plan d鈥橧ncitation en Actions d鈥橧nduction de BioCryst, conform茅ment 脿 la r猫gle de cotation Nasdaq 5635(c)(4).
BioCryst Pharmaceuticals (Nasdaq: BCRX) gab die Gew盲hrung von Aktienoptionen und Restricted Stock Units (RSUs) an 10 neu eingestellte Mitarbeiter als Einstellungsanreiz bekannt. Der Verg眉tungsausschuss genehmigte Optionen zum Kauf von 36.700 Aktien und RSUs f眉r 89.750 Aktien des Stammkapitals.
Die Optionen wurden zu einem Aus眉bungspreis von 7,95 $ pro Aktie gew盲hrt, entsprechend dem Schlusskurs von BioCryst am 1. August 2025. Sowohl Optionen als auch RSUs werden 眉ber vier gleiche j盲hrliche Raten ab einem Jahr nach dem Gew盲hrungsdatum erworben, wobei die Optionen eine Laufzeit von 10 Jahren haben. Diese Gew盲hrungen erfolgten im Rahmen des Inducement Equity Incentive Plans von BioCryst gem盲脽 der Nasdaq-Listing-Regel 5635(c)(4).
- None.
- Potential dilution of existing shareholders from new equity grants
RESEARCH TRIANGLE PARK, N.C., Aug. 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that the compensation committee of BioCryst鈥檚 board of directors granted 10 newly-hired employees stock options to purchase an aggregate of 36,700 shares, and restricted stock units (RSUs) covering an aggregate of 89,750 shares, of BioCryst common stock. The options and RSUs were granted as of August 1, 2025, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO庐 (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit or follow us on .
BCRXW
Contact:
Investors:
[email protected]
Media:
[email protected]
FAQ
How many shares were granted in BioCryst's (BCRX) latest inducement grants?
What is the exercise price for BCRX's newly granted stock options?
What is the vesting schedule for BioCryst's (BCRX) new equity grants?
How long is the term of BioCryst's newly granted stock options?
Under which rule were BioCryst's inducement grants made?
